| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/24/2001 | CN1061043C Benzo-iso-thiazolyl substituted amino methyl benzodipyran |
| 01/24/2001 | CN1061041C Piperidine derivatives |
| 01/24/2001 | CN1061036C Substituted pyrazolyl benzenesulfonamides for treating inflammation |
| 01/24/2001 | CN1061035C Phenylalkanolamine derivatives and its preparing process and use |
| 01/24/2001 | CN1060957C Narcotics-giving-up oral liquor and its preparing method |
| 01/24/2001 | CN1060948C Auxiliary table and aspirin in application for treating mental retardation |
| 01/23/2001 | USRE37029 Antipsychotic and analgesic agents |
| 01/23/2001 | US6177458 Alzheimer's disease |
| 01/23/2001 | US6177451 For humans; parkinson's, tourelle's, and alzheimer's diseases |
| 01/23/2001 | US6177445 Substituted isoquinolines as ultra short acting neuromuscular blockers |
| 01/23/2001 | US6177444 Allosteric adenosine receptor modulators |
| 01/23/2001 | US6177429 Dihydropyrazine derivatives as NPY antagonists |
| 01/23/2001 | US6177428 Treatment of sexual dysfunction; stimulation of endogenous nitrogen monoxide synthesis |
| 01/23/2001 | US6177419 Antioxidant chelate compounds for preventing oxygen free radical-associated diseases in mammals; neuroprotectants, superoxide dismutase (sod), catalase (cat) and/or peroxidase (pod) mimetics |
| 01/23/2001 | US6177402 Promoting survival of mammalian sensory neurons by contacting with leukemia inhibitory factor (lif) |
| 01/23/2001 | US6177246 Contacting a tissue or cell with an oligonucleotide of defined nucleotide sequence which hybridizes to nucleic acid encoding abnormally expressed beta-amyloid precursor protein; prophylaxis and treatment of alzheimer's disease |
| 01/23/2001 | US6177077 TNT inhibitors for the treatment of neurological disorders |
| 01/23/2001 | CA2314473A1 New b-carboline derivatives, a procedure for preparing them and the pharmaceutical compounds containing them |
| 01/23/2001 | CA2219631C Pyrrolidinyl methyl indole salt |
| 01/23/2001 | CA2197451C Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives |
| 01/23/2001 | CA2197272C Pro-drugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6- chloro-1,3-dihydro-2h-indol-2-one |
| 01/23/2001 | CA2196885C Carboxamide compounds (changed to n-(2-(pyrrolidinyl-1)-1-phenylethyl) acetamides as kappa receptor antagonists) |
| 01/23/2001 | CA2128202C Alkyl derivatives of trazodone with cns activity |
| 01/23/2001 | CA2031079C Aminocarbonylcarbamates related to physostigmine, a process for their preparation and their use as medicaments |
| 01/23/2001 | CA2022451C Anti-psychotic piperidynl benzimidazole compounds |
| 01/23/2001 | CA2019717C (1,2,3,4-tetrahydro-9-acridinimino)cyclohexane carboxylic acid and related compounds, a process for their preparation and their use as medicaments |
| 01/22/2001 | CA2746824A1 Neurotherapeutic composition and method |
| 01/18/2001 | WO2001004349A2 Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease |
| 01/18/2001 | WO2001004341A1 Method for producing oligopolysaccharides |
| 01/18/2001 | WO2001004318A2 Myxoma virus genes for immune modulation |
| 01/18/2001 | WO2001004312A1 Proliferation differentiation factor |
| 01/18/2001 | WO2001004308A1 Human lim domain proteins |
| 01/18/2001 | WO2001004305A2 Human proteins involved in detoxification |
| 01/18/2001 | WO2001004300A1 Apoptosis-associated factor |
| 01/18/2001 | WO2001004299A1 AMYLOID β PROTEIN AGGLUTINATION CONTROLLING FACTOR |
| 01/18/2001 | WO2001004298A1 Novel physiologically active substance, process for producing the same and use thereof |
| 01/18/2001 | WO2001004297A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 01/18/2001 | WO2001004157A2 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS |
| 01/18/2001 | WO2001004133A1 Human eag2 |
| 01/18/2001 | WO2001004124A1 OXATHIEPINO[6,5-b]DIHYDROPYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 01/18/2001 | WO2001004122A2 New 2,3-benzodiazepine derivatives |
| 01/18/2001 | WO2001004119A1 Amido spiropiperidines promote the release of growth hormone |
| 01/18/2001 | WO2001004116A2 Neurotrophic pyrrolidines and piperidines, and related compositions containing them |
| 01/18/2001 | WO2001004113A2 Process for the preparation of paroxetine and synthetic intermeditates thereof |
| 01/18/2001 | WO2001004112A2 Benzofurane derivatives |
| 01/18/2001 | WO2001004107A1 SUBSTITUTED α,β-ANELLATED BUTYROLACTONES |
| 01/18/2001 | WO2001004106A1 Process for producing dibenzothiazepine derivatives |
| 01/18/2001 | WO2001004099A1 Benzoylpyridazines |
| 01/18/2001 | WO2001004091A1 Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods |
| 01/18/2001 | WO2001003743A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | WO2001003737A1 Immunoglobulin fusion proteins |
| 01/18/2001 | WO2001003720A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | WO2001003712A1 Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement |
| 01/18/2001 | WO2001003710A1 Analgesic from snake venom |
| 01/18/2001 | WO2001003704A1 Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis |
| 01/18/2001 | WO2001003696A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/18/2001 | WO2001003694A1 Treatment of neurotic disorders |
| 01/18/2001 | WO2001003692A1 Compositions and methods for promoting nerve regeneration |
| 01/18/2001 | WO2001003689A1 Antianxiety drugs |
| 01/18/2001 | WO2001003688A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 01/18/2001 | WO2001003684A2 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 01/18/2001 | WO2001003680A2 Compounds for inhibiting diseases and preparing cells for transplantation |
| 01/18/2001 | WO2001003668A1 Pulmonary delivery of liposome-encapsulated cannabinoids |
| 01/18/2001 | WO2001003649A2 Compositions and methods for the treatment of parkinson's disease |
| 01/18/2001 | WO2001003648A2 Oregano-based therapeutic composition |
| 01/18/2001 | WO2000063415A8 Dna encoding the human vanilloid receptor vr1 |
| 01/18/2001 | WO2000055180A3 Human lung cancer associated gene sequences and polypeptides |
| 01/18/2001 | WO2000047723A3 Human diacylglycerol kinase beta (hdagk beta) proteins and nucleotide sequences encoding the same |
| 01/18/2001 | WO2000019210A3 Determining the mechanism of beta-amyloid peptide generation |
| 01/18/2001 | WO2000002911A3 INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) |
| 01/18/2001 | DE19933089A1 Mittel zur Gewerbsregeneration Means for commercial regeneration |
| 01/18/2001 | DE19930625A1 Pure thiuram disulfide preparation in high yield, for use e.g. as rubber vulcanization accelerator or anti-alcoholism drug, by reacting amine with carbon disulfide and lithium hydroxide then oxidizing with hydrogen peroxide |
| 01/18/2001 | CA2687396A1 Treatment of neurotic disorders |
| 01/18/2001 | CA2687394A1 Treatment of neurotic disorders |
| 01/18/2001 | CA2687392A1 Treatment of neurotic disorders |
| 01/18/2001 | CA2416233A1 Compositions and methods for the treatment of parkinson's disease |
| 01/18/2001 | CA2379373A1 Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins |
| 01/18/2001 | CA2379199A1 Oxathiepino[6,5-b]dihydropyridines, and related compositions and methods |
| 01/18/2001 | CA2379149A1 Neurotrophic pyrrolidines and piperidines, and related compositions and methods |
| 01/18/2001 | CA2379133A1 Human proteins involved in detoxification |
| 01/18/2001 | CA2378989A1 Human lim domain proteins |
| 01/18/2001 | CA2378610A1 Human eag2 |
| 01/18/2001 | CA2378595A1 Benzoylpyridazines |
| 01/18/2001 | CA2378567A1 Novel myxoma genes for immune modulation |
| 01/18/2001 | CA2378562A1 Method for producing oligopolysaccharides |
| 01/18/2001 | CA2378485A1 Proliferation differentiation factor |
| 01/18/2001 | CA2378465A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | CA2378305A1 New 2,3-benzodiazepine derivatives |
| 01/18/2001 | CA2378179A1 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | CA2377918A1 Compositions and methods for promoting nerve regeneration |
| 01/18/2001 | CA2377914A1 Analgesic from snake venom |
| 01/18/2001 | CA2377502A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/18/2001 | CA2375628A1 Compounds for inhibiting diseases and preparing cells for transplantation |
| 01/18/2001 | CA2341035A1 Pulmonary delivery of liposomal-encapsulated cannabinoids |
| 01/17/2001 | EP1069125A2 Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs, a process for their preparation and their use as medicaments |
| 01/17/2001 | EP1069124A1 2-Benzimidazolylamine compounds as ORL1-receptor agonists |
| 01/17/2001 | EP1069106A2 Dimethyl-(3-aryl-but-3-enyl) amine derivatives with analgesic activity |
| 01/17/2001 | EP1068315A2 Therapeutic agent for ngf |
| 01/17/2001 | EP1068308A1 Secreted proteins and polynucleotides encoding them |
| 01/17/2001 | EP1068299A2 Use of stimulated peripheral blood mononuclear cells for the treatment of brain-related diseases, disorders and damage |